Startups channel feed

Af­ter decades in the big leagues, Mar­tin Mack­ay is go­ing small — and he's de­light­ed

8 years ago
People
Financing

Pro­tein degra­da­tion 2.0? Third Rock sinks $56M in­to Cedil­la's un­usu­al ap­proach

8 years ago
Financing

VC be­liev­ers back a $41M game plan for En­ter­prise Ther­a­peu­tic­s' new group of res­pi­ra­to­ry drugs

8 years ago
Financing

Vivek Ra­maswamy is div­ing in­to RNA, launch­ing a new biotech with Ar­bu­tus and a team of vets

8 years ago
People

Har­vard big-shots Kevin Eggan and Clif­ford Woolf launch ALS start­up with ex­clu­sive Q-State tech

8 years ago

Roche grabs a re­myeli­na­tion MS drug from Ver­sant as the re­search team spins out in­to a $25M re­gen­er­a­tive med start­up

8 years ago
Pharma

Eli Lil­ly hands transpa­cif­ic biotech up­start Terns pieces to an ex­per­i­men­tal NASH puz­zle

8 years ago
Pharma

Arie Bellde­grun rais­es $300M, grabs Pfiz­er’s al­lo­gene­ic CAR-T port­fo­lio and launch­es a ground­break­ing dri­ve to com­mer­cial­iza­tion

8 years ago
Financing

Backed by gi­ants, an­tibi­otics up­start Macrolide gets $20M and an ex-No­var­tis ex­ec as CEO

8 years ago
People
Financing

Chi­nese on­col­o­gy start­up Ada­gene clos­es $50M Se­ries C led by Se­quoia Cap­i­tal

8 years ago
Financing
China

With ma­jor fund­ing from No­var­tis, Sur­face On­col­o­gy launch­es a CD47 tri­al amid a swarm of ri­vals and files for $75M IPO

8 years ago
Financing

Backed in part by Roche, Den­mark's NMD gets $47M to run or­phan neu­ro­mus­cu­lar dis­ease tri­als

8 years ago
Financing

Third Rock de­buts im­munome­tab­o­lism start­up Rheos with $60M launch round

8 years ago
Financing

CRISPR pi­o­neer Feng Zhang co-founds a 'lim­it­less' biotech up­start with big plans for speed­ing new drug de­vel­op­ment

8 years ago
Financing

An im­munother­a­py pill for pso­ri­a­sis? Es­calier gets $19M Se­ries B to tack­le R&D

8 years ago

Pre­vail grabs $75M A round in the hunt for new gene ther­a­pies to stop the de­struc­tion caused by Parkin­son's

8 years ago
Financing

SF tech start­up Atom­wise gets $45M for AI-pow­ered drug de­sign soft­ware

8 years ago
Financing
AI

Is tech mon­ey bad for busi­ness? Sil­i­con Val­ley cash makes some bio­phar­ma VCs bris­tle, oth­ers cheer

8 years ago
Financing
Bioregnum

Unum plays its first glimpse of hu­man da­ta in an $86M IPO, re­veal­ing two deaths and an FDA hold

8 years ago
Financing
Pharma

Asian in­vestor com­mits $15M to launch new pro­tein degra­da­tion biotech start­up Cull­gen out of UNC

8 years ago

Dana-Far­ber’s Lau­rie Glim­ch­er helps launch a NYC biotech up­start with some key in­sights on im­muno-on­col­o­gy tech

8 years ago
Financing

Haul­ing in a $100M mega-round, gene ther­a­py start­up Gen­er­a­tion Bio builds al­ter­na­tive to po­ten­tial­ly risky vi­ral vec­tors

8 years ago
Financing
Cell/Gene Tx

Com­put­er sci­ence and en­gi­neer­ing, meet drug R&D. MIT star Tim­o­thy Lu in­ter­twines tech­nolo­gies for an off­beat biotech launch

8 years ago
Financing

Up­start GeneTx launch­es, go­ing head to head with Ovid on rare An­gel­man syn­drome

8 years ago
First page Previous page 64656667686970 Next page Last page
A service from the Financial Times